Company news

IDEAYA Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

September 1, 2025

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

August 28, 2025

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

August 24, 2025

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

August 17, 2025

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

August 4, 2025

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

July 23, 2025

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

July 22, 2025

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

July 21, 2025

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

July 20, 2025

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

June 1, 2025

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

May 5, 2025

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

April 27, 2025

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

April 13, 2025

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

April 9, 2025

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

March 31, 2025

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

March 30, 2025

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

March 25, 2025

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

March 2, 2025

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 12, 2025

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

February 12, 2025

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

February 9, 2025

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

January 26, 2025

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

January 11, 2025

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

December 28, 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

December 16, 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

December 15, 2024

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

December 10, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

December 9, 2024

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

December 8, 2024

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

December 1, 2024

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

November 17, 2024

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

November 11, 2024

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

November 10, 2024

Correction: IDEAYA Biosciences, Inc.

November 3, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

October 27, 2024

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

October 24, 2024

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

October 3, 2024

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

September 22, 2024

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

September 21, 2024

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

September 17, 2024

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 25, 2024

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

July 30, 2024

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

July 28, 2024

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

July 10, 2024

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

July 8, 2024

IDEAYA Announces Pricing of Public Offering

July 8, 2024

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

July 7, 2024

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

July 4, 2024

← Newer news releases · Older news releases →

Decks

The 5 newest of 23 decks. Every deck is listed under its year.